After-Hours Stock Movers 11/15: (LZB) (ACRS) (A) Higher; (PDLI) (FLXN) (NVTA) Lower (more...)

November 15, 2016 5:56 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's After-Hours Movers

PDL BioPharma, Inc. (NASDAQ: PDLI) 8.9% LOWER; announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes

Flexion Therapeutics, Inc. (Nasdaq: FLXN) 7.9% LOWER; announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Invitae Corporation (NYSE: NVTA) 6.2% LOWER; announced that it has commenced an underwritten public offering of $40 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

La-Z-Boy Incorporated (NYSE: LZB) 5% HIGHER; signed an agreement to acquire the license for the La-Z-Boy brand in the United Kingdom and Ireland from Furnico Ltd., which has been La-Z-Boys sales and distribution partner in the market for the past eight years. Annual wholesale revenue for this business is approximately $42 million, based on current exchange rates. Due to the licensing agreement in place today, La-Z-Boy Incorporated already captures approximately half of the sales volume. The agreement will be effective January 1, 2017, and its results will be reported in the companys upholstery segment. The existing Furnico business outside of the La-Z-Boy license will continue with its normal operations.

M/A-Com Technology Solutions (NASDAQ: MTSI) 3.6% LOWER; reported Q4 EPS of $0.54, $0.02 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $152.7 million versus the consensus estimate of $149.97 million. GUIDANCE: M/A-Com Technology Solutions sees Q1 2017 EPS of $0.54-$0.58, versus the consensus of $0.58. M/A-Com Technology Solutions sees Q1 2017 revenue of $150-154 million, versus the consensus of $150.3 million.

ViaSat Inc. (Nasdaq: VSAT) 2.6% LOWER; announced that it has commenced an underwritten public offering of 6,500,000 shares of its common stock.

Aclaris Therapeutics, Inc. (Nasdaq: ACRS) 1.4% HIGHER; announced that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution (A-101), a novel treatment for seborrheic keratosis (SK) met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of SK lesions.

Agilent Technologies (NYSE: A) 0.8% HIGHER; reported Q4 EPS of $0.59, $0.07 better than the analyst estimate of $0.52. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.07 billion. GUIDANCE: Agilent Technologies sees Q1 2017 EPS of $0.48-$0.50, versus the consensus of $0.53. Agilent Technologies sees Q1 2017 revenue of $1.04-1.06 billion, versus the consensus of $1.08 billion. Agilent Technologies sees FY2017 EPS of $2.10-$2.16, versus the consensus of $2.19. Agilent Technologies sees FY2017 revenue of $4.35-4.37 billion, versus the consensus of $4.35 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

After-Hours Movers, Definitive Agreement

Add Your Comment